GABA (Gamma-Aminobutyric Acid)

As the brain's chief inhibitory neurotransmitter, GABA reduces neuronal firing by binding to GABA-A receptors (ligand-gated chloride ion channels) and GABA-B receptors (G-protein coupled receptors). GABA-A receptor activation increases chloride ion influx, hyperpolarizing the neuron and making it less likely to fire. This mechanism underlies the effects of benzodiazepines, barbiturates, and alcohol, all of which enhance GABA-A signaling. The central question with oral GABA supplementation is blood-brain barrier (BBB) permeability. Conventionally, GABA has been considered unable to cross the BBB in significant quantities due to its hydrophilic nature. However, more recent research challenges this assumption. Boonstra et al. (2015) reviewed evidence suggesting that small but physiologically meaningful amounts may cross the BBB, and that the BBB may be more permeable to GABA than previously believed, particularly in areas like the circumventricular organs. Additionally, GABA may exert peripheral effects through the enteric nervous system, influencing mood and relaxation via the gut-brain axis. PharmaGABA, produced by Lactobacillus hilgardii fermentation, may have superior bioactivity compared to synthetic GABA, with EEG studies showing increased alpha wave activity and reduced beta waves within 60 minutes of ingestion, suggesting central effects regardless of the BBB debate.

The evidence base for oral GABA supplementation is growing but remains preliminary compared to established anxiolytics. Abdou et al. (2006) demonstrated that oral GABA (100 mg) increased alpha wave production and decreased beta waves on EEG within 60 minutes, and reduced anxiety markers including salivary IgA levels during a stress-inducing task, suggesting meaningful central effects. Yamatsu et al. (2016) conducted a randomized placebo-controlled trial showing that 100 mg GABA reduced sleep latency and improved sleep quality within one week, with effects maintained at four weeks. The study also measured GABA levels in hair samples and correlated them with sleep improvements. Boonstra et al. (2015) published a comprehensive review in Frontiers in Psychology addressing the BBB controversy, concluding that while the mechanism remains debated, clinical evidence supports meaningful neurobehavioral effects of oral GABA. Yoto et al. (2012) showed that 100 mg oral GABA ameliorated the decline in cognitive function and mood induced by mental stress. For exercise-related benefits, Powers et al. (2008) found that GABA supplementation increased growth hormone (HGH) levels at rest and after resistance exercise, though the clinical significance of transient HGH elevations remains debated. Overall, GABA supplementation shows consistent stress-reduction and sleep-onset effects, but the mechanisms may involve peripheral as well as central pathways.

Gamma-aminobutyric acid, PharmaGABA (natural fermentation form)

The oral bioavailability of GABA for central nervous system effects remains debated. GABA is hydrophilic and was traditionally thought to have poor BBB penetration. However, clinical studies demonstrating EEG changes, stress reduction, and sleep improvement within 30–60 minutes of oral dosing suggest clinically relevant bioactivity. PharmaGABA may have superior bioactivity compared to synthetic GABA, possibly due to its natural isomeric configuration.

• Fermented foods (kimchi, miso, tempeh — GABA produced by fermentation)
• Germinated brown rice (GABA rice)
• Green tea (contains both GABA and L-theanine)
• Tomatoes
• Spinach and sweet potatoes
• Fermented soy products (natto)